Skip to content
10-Q

Quarterly Report

Celldex Therapeutics, Inc. CLDX

0001104659-25-109137

← back to feed
Filed
Nov 10, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 29, 2025 66.45M sh
Shares Diluted Q3 2025 · Sep 30, 2025 66.42K sh
Shares Diluted Q3 2025 · Sep 30, 2025 66.4K sh
Shares Diluted Q3 2025 · Sep 30, 2024 66.29K sh
Shares Diluted Q3 2025 · Sep 30, 2024 63.74K sh
Capex Q3 2025 · Sep 30, 2025 $1.43M
Capex Q3 2025 · Sep 30, 2024 $1.16M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$147.01M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$125.3M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $36.04M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $28.36M
Stockholders Equity Q3 2025 · Sep 30, 2025 $598.36M
Stockholders Equity Q3 2025 · Jun 30, 2025 $655.41M
Stockholders Equity Q3 2025 · Mar 31, 2025 $702.98M
Stockholders Equity Q3 2025 · Dec 31, 2024 $747.01M
Stockholders Equity Q3 2025 · Sep 30, 2024 $785.91M
Stockholders Equity Q3 2025 · Jun 30, 2024 $813.66M
Stockholders Equity Q3 2025 · Mar 31, 2024 $838.61M
Stockholders Equity Q3 2025 · Dec 31, 2023 $429.17M
Current Liabilities Q3 2025 · Sep 30, 2025 $46.47M
Current Liabilities Q3 2025 · Dec 31, 2024 $39.5M
Total Liabilities Q3 2025 · Sep 30, 2025 $50.08M
Total Liabilities Q3 2025 · Dec 31, 2024 $45.34M
Current Assets Q3 2025 · Sep 30, 2025 $604.34M
Current Assets Q3 2025 · Dec 31, 2024 $747.16M
Total Assets Q3 2025 · Sep 30, 2025 $648.44M
Total Assets Q3 2025 · Dec 31, 2024 $792.34M
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.01
Eps Diluted Q3 2025 · Sep 30, 2025 −$2.67
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.64
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.74
Eps Basic Q3 2025 · Sep 30, 2025 −$1.01
Eps Basic Q3 2025 · Sep 30, 2025 −$2.67
Eps Basic Q3 2025 · Sep 30, 2024 −$0.64
Eps Basic Q3 2025 · Sep 30, 2024 −$1.74
Sga Expense Q3 2025 · Sep 30, 2025 $10.69M
Sga Expense Q3 2025 · Sep 30, 2025 $31.9M
Sga Expense Q3 2025 · Sep 30, 2024 $10.05M
Sga Expense Q3 2025 · Sep 30, 2024 $28.29M
Rd Expense Q3 2025 · Sep 30, 2025 $62.93M
Rd Expense Q3 2025 · Sep 30, 2025 $169.74M
Rd Expense Q3 2025 · Sep 30, 2024 $45.26M
Rd Expense Q3 2025 · Sep 30, 2024 $116.61M
Net Income Q3 2025 · Sep 30, 2025 −$67.04M
Net Income Q3 2025 · Sep 30, 2025 −$177.44M
Net Income Q3 2025 · Jun 30, 2025 −$56.6M
Net Income Q3 2025 · Mar 31, 2025 −$53.8M
Net Income Q3 2025 · Sep 30, 2024 −$42.12M
Net Income Q3 2025 · Sep 30, 2024 −$110.77M
Net Income Q3 2025 · Jun 30, 2024 −$35.84M
Net Income Q3 2025 · Mar 31, 2024 −$32.81M
Operating Income Q3 2025 · Sep 30, 2025 −$73.62M
Operating Income Q3 2025 · Sep 30, 2025 −$200.21M
Operating Income Q3 2025 · Sep 30, 2024 −$52.13M
Operating Income Q3 2025 · Sep 30, 2024 −$139.05M
Revenue Q3 2025 · Sep 30, 2025 $1.42M
Revenue Q3 2025 · Sep 30, 2024 $3.19M
Revenue Q3 2025 · Sep 30, 2024 $5.85M